Phase 4 N=66 ICE-T Pain Regimen for Total Laparoscopic Hysterectomy
Opioid Substitution Treatment
Primary: POD1 Visual Analog Pain (VAS) Score — 5.8; 5 Score on a scale — p=.16
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=42 Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Mean Change From Baseline in Serum Potassium Levels Over 24 Hours — 4.3; 0.25; 0.60; 0.49 mmol/L
Phase 2 N=190 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology — 51.84; 63.13; 73.92; 12.62 Percentage…
N/A N=42 Evaluating Household Food Behavior With a Smartphone App
Food Habits
Primary: Phase 1: Food Waste Error — -16.25; 31.34; 20553.6 grams
N/A N=190 Testing Financial Incentive Interventions in Dyadic-Smoker Couples
Nicotine Dependence
Primary: Smoking Abstinence — 4; 16; 9; 25 Targets
N/A N=3,000 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study
Abdominal Surgery
Primary: Disability-free Survival — 165; 172 Participants
Phase 2 N=48 Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
Metastatic Non Small Cell Lung Cancer
Primary: Immune Related Progression Free Survival (irPFS) at 1 Year — 16 Participants
N/A N=1,103 Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling
Type II Diabetes
Primary: Priority Scores for Potential Barriers and Facilitators for Diabetes Self-management — 0.505; 0.327; 0.500; 0.369 units on a scale
Phase 2 N=135 A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
HER2-negative Breast Cancer
Primary: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) — -62.7; -62.8; -67.1; -66.9…
Phase 4 N=984 SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
HIV
Primary: Biomedical Prevention Covered Time — 69.7; 13.3 % of days
N/A N=128 Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Acute Myeloid Leukemia · Brain Glioblastoma · Estrogen Receptor Negative
Primary: Number of Emergency Department Visits (Chart Review) — 1.33; 0.41 visits
N/A N=50 Scottish Vitamin D Intervention Study
GENE EXPRESSION · Colorectal Cancer
Primary: Number of Genes Significantly Associated With 25OHD Blood Vitamin D Level — 629 significant probes (P<0.01)
N/A N=76 mHealth for Breast Cancer Survivors With Insomnia
Breast Cancer Survivor · Insomnia
Primary: Insomnia Symptoms — -8.4; -2.6 units on a scale — p=<0.05
Phase 1 N=96 Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
Typhoid Fever
Primary: Number of Participants With Solicited Administration-site Events After the First Vaccination — 3; 11; 20; 22 Participants
N/A N=202 Telehealth Pain Self-Management for Employed Adults
Chronic Pain · Brain Injuries, Traumatic · Multiple Sclerosis
Primary: Change in Pain Interference — -4.0; -1.3 T-score — p=0.004